Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01331473
Other study ID # PROVENON01
Secondary ID
Status Recruiting
Phase Phase 3
First received March 30, 2011
Last updated December 2, 2011
Start date May 2011
Est. completion date June 2014

Study information

Verified date March 2011
Source Saarland University
Contact Panagiotis Papanagiotou, MD
Phone +49684116
Email provenon.study@me.com
Is FDA regulated No
Health authority Germany: Ethics Commission
Study type Interventional

Clinical Trial Summary

To compare the incidence of new ischemic brain injury detected with magnetic resonance imaging (MRI) after carotid artery stenting in patients treated with and without proximal cerebral protection (Gore Flow Reversal System).


Description:

Primary Objective:

The purpose of this study is to compare the rate of new ischemic brain injury detectable on MRI after carotid artery stenting between patients treated with proximal cerebral protection (Gore Flow Reversal System) and without cerebral protection.

Secondary Objective:

Impact of MRI-morphology of atherosclerotic plaque to the rate of new hyperintense diffusion weighted imaging (DWI) lesion on the post-treatment scan and to the rate of ipsilateral stroke or death.


Recruitment information / eligibility

Status Recruiting
Enrollment 220
Est. completion date June 2014
Est. primary completion date May 2014
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Male and female = 18 years old;

- Suitable/Eligible for carotid artery revascularization;

- Significant artery stenosis in symptomatic patients defined as = 50% of the artery diameter (%DS) or asymptomatic = 80 %DS by angiography. Symptomatic is defined as a carotid artery stenosis associated with ipsilateral transient ischemic attack (TIA), amaurosis fugax, ischemic stroke or retinal infarction within 6 months prior to enrollment.

- Adequate clinical conditions to perform DW-MRI.

- Ability of the individual to understand the character and the consequences of clinical trial.

- Signed and dated informed consent provided before the beginning of any intervention.

- Negative pregnancy test (serum or urine) and contraception use for any woman of childbearing age. Systematic contraceptives (oral, implant, injection) and dia-phragm or condoms with spermicidal are considered reliable. Women who have undergone bilateral oophorectomy or/and hysterectomy or women status post-menopausal for at least two years are eligible for this trial.

Exclusion Criteria:

- Intracranial hemorrhage, hemorrhagic stroke, or stroke with mass effect demonstrated on CT scan or MRI within 30 days of the index procedure.

- Persisting ischemic stroke (defined as either a score > 15 on the NIH stroke scale, a Rankin score > 3 or a Barthel score < 60 measured within one week prior to study entry).

- Intracranial mass lesion (i.e., abscess, tumor, or other infection).

- peripheral vascular, supra-aortic or internal carotid artery tortuosity precluding the use of catheter-based techniques required for successful results.

- Lactation.

- Arterio-venous malformation in the territory of the target carotid artery.

- Any disease or medication that affects local hemostasis,

- Participation in other clinical trials during the present clinical trial or within the last month.

- Medical or psychological condition that would not permit completion of the trial or signing of informed consent.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Procedure:
Carotid Artery Stenting with Proximal Protection
Carotid artery angioplasty and stenting with proximal embolic protection provided by the GORE Neuro Protection System
Carotid Artery Stenting without Protection
Carotid artery angioplasty and stenting without cerebral embolic protection

Locations

Country Name City State
Germany Department of Diagnostic and Interventional Neuroradiology Homburg Saarland

Sponsors (1)

Lead Sponsor Collaborator
Saarland University

Country where clinical trial is conducted

Germany, 

References & Publications (3)

Grunwald IQ, Papanagiotou P, Roth C, Fassbender K, Karp K, Krick C, Schieber H, Müller M, Haass A, Reith W. Lesion load in unprotected carotid artery stenting. Neuroradiology. 2009 May;51(5):313-7. doi: 10.1007/s00234-008-0491-6. Epub 2009 Feb 6. — View Citation

Grunwald IQ, Papanagiotou P, Struffert T, Politi M, Krick C, Romaike BF, Ahlhelm F, Reith W. Reversal of flow during carotid artery stenting: use of the Parodi antiembolism system. Neuroradiology. 2007 Mar;49(3):237-41. Epub 2007 Jan 5. — View Citation

Kastrup A, Nägele T, Gröschel K, Schmidt F, Vogler E, Schulz J, Ernemann U. Incidence of new brain lesions after carotid stenting with and without cerebral protection. Stroke. 2006 Sep;37(9):2312-6. Epub 2006 Aug 3. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary The detection rate of new hyper-intense DWI lesion on the post-treatment compared to the pretreatment MRI imaging Day 1-3
Secondary Ipsilateral stroke (ischaemic stroke, intracerebral bleeding or both, with symptoms lasting more than 24 h) or death between treatment and 30 days after treatment Day 30
Secondary Technical Success of the procedure Subjects (both groups) who due to technical reaseons are unable to performe carotid artery stenting will be considered as technical failures.
Subjects who are unable to tolerate flow reversal (in group 2) and have their procedures completed without embolic protection or other methods will be also considered as technical failures.
Day 0
Secondary Access site vascular complications, defined as need for surgical repair or blood transfusion Day 0-7
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03931161 - Effect of Evolocumab on Carotid Plaque Composition in Asymptomatic Carotid Artery Stenosis (EVOCAR-1) Phase 4
Recruiting NCT03353103 - Imaging of Unstable Carotid Plaque in Patient Referred to Endarterectomy Phase 2
Completed NCT03996148 - Time to Post-Anesthesia Neurological Evaluation With Three Different Anesthetic Techniques Phase 4
Recruiting NCT05968053 - Detection of Microplastics and Nanoplastics in Neurosurgery Patients (DT-MiNi)
Completed NCT00597974 - Neurological Outcome With Carotid Artery Stenting N/A
Completed NCT00318851 - Carotid Artery Stenting With Protection Registry Phase 3
Active, not recruiting NCT05293067 - Troponin In Carotid Revascularization
Completed NCT03133429 - Clinical Study to Evaluate the Safety and Effectiveness of MER® Stents in Carotid Revascularisation. N/A
Recruiting NCT01440036 - The Correlation Between the Enzyme Paraoxigenase 1 (PON1) to Carotid Artery Atheromatous Plaque N/A
Completed NCT00417963 - ViVEXX Carotid Revascularization Trial (VIVA) Phase 3
Completed NCT00177346 - A Randomized Trial of Carotid Artery Stenting With and Without Cerebral Protection N/A
Recruiting NCT05574972 - Timing Carotid Stent Clinical Study for the Treatment of Carotid Artery Stenosis(Timing Trial) N/A
Recruiting NCT02476396 - Structural Stability of Carotid Plaque and Symptomatology
Completed NCT05451485 - VFI in Healthy Vessels
Recruiting NCT06033963 - Safety and Efficacy of Remote Ischemic Conditioning in Patients With Carotid Artery Stenosis Receiving Carotid EndArterectomy N/A
Not yet recruiting NCT02224209 - Comparison of Staged Angioplasty and Routine Single-stage Stenting (CAS) in the Treatment of Carotid Artery Stenosis Phase 4
Completed NCT02006095 - Neuroimaging Correlates of Memory Decline Following Carotid Interventions
Terminated NCT01236508 - Relation of Carotid Artery Plaque Inflammation, Covert Stroke and White Matter Disease Phase 4
Recruiting NCT05126238 - A Lithium-Based Medication to Improve Neurological Outcomes After Surgical Carotid Reconstruction Phase 3
Recruiting NCT06170580 - Improved Image Quality for Assessment of Carotid Artery Stenosis by Ultrafast Ultrasound FLOW Imaging